Surface Modification of Liposomes by a Lipopolymer Targeting Prostate Specific Membrane Antigen for Theranostic Delivery in Prostate Cancer
Prostate specific membrane antigen (PSMA) is a marker for diagnosis and targeted delivery of therapeutics to advanced/metastasized prostate cancer. We report a liposome-based system for theranostic delivery to PSMA-expressing (PSMA+) LNCaP cells. A lipopolymer (P3) comprising of PSMA ligand (PSMAL),...
Main Authors: | Hooman Yari, Gregory Nkepang, Vibhudutta Awasthi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-03-01
|
Series: | Materials |
Subjects: | |
Online Access: | http://www.mdpi.com/1996-1944/12/5/756 |
Similar Items
-
Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective
by: Thomas S. C. Ng, et al.
Published: (2021-07-01) -
Theranostics in Oncology—Thriving, Now More than Ever
by: Rudolf A. Werner, et al.
Published: (2021-04-01) -
PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives
by: Mohamed El Fakiri, et al.
Published: (2021-08-01) -
Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
by: Ayman Abouzayed, et al.
Published: (2019-07-01) -
Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
by: Katharina Kessel, et al.
Published: (2021-07-01)